Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Oxford Biomedica plc is a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapy viral vectors. Founded in 1996 and headquartered in Oxford, UK, the company pioneers advanced bioprocessing for lentiviral, adeno-associated virus (AAV), adenovirus, and other vector types, supporting clients from early-stage development to commercial GMP manufacturing. Its proprietary technologies, including the LentiVector® platform and TetraVecta™ 4th generation lentiviral system, enable scalable production of therapies targeting cancers, Parkinson’s, CNS disorders, and ocular conditions. Operating a global network with facilities in the UK, France, and the US, Oxford Biomedica plc serves pharmaceutical and biotech partners in biotechnology, clinical vaccines, and bioprocessing sectors. With over 30 years of experience, robust quality systems, and regulatory expertise, it facilitates life-changing therapies, evidenced by numerous successful audits, GMP batches, and products approved in multiple countries.
£6.19
£0.25 (-3.88%)
EOD Jul 3, 2026
The business is unprofitable at the operating level (-19.53% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 31.0% YoY with margins expanding 14.2pp.
Negative free cash flow of -£4M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£169M
▲ +31.0% YoY
Net Income (TTM)
-£31M
▲ +37.0% YoY
Op. Margin
-19.53%
▲ +14.2pp YoY
ROIC
-12.74%
▲ +6.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£4M
▲ +92.7% YoY
Op. Cash Flow (TTM)
£507K
▲ +101.0% YoY
Net Debt
£51M
Cash & Equiv.
£97M
3Y CAGR: +6.4%
Continue Research
Oxford Biomedica (OXB.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Oxford Biomedica scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Oxford Biomedica scores 26 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -19.5% operating margin and a -12.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OXB.XLON's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.